dr. daniel petrylak explains the correlation between immune response to sipuleucel-t and survival
Published 11 years ago • 353 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:11
dr. daniel petrylak on sipuleucel-t delaying time to first opioid use
-
0:47
dr. daniel petrylak describes the clinical investigation of prostvac in prostate cancer
-
1:38
dr. lawrence fong discusses immune response to sipuleucel-t
-
1:21
dr. petrylak explains prostate cancer clinical trial difficulties
-
0:47
dr. petrylak on the recent developments in prostate cancer
-
1:43
dr. petrylak discusses sequencing prostate cancer therapies
-
1:10
dr. daniel petrylak discusses chemotherapy in prostate cancer
-
1:03
dr. daniel petrylak on the role of enzalutamide in prostate cancer
-
1:05
dr. petrylak on psma adc for patients with mcrpc
-
1:43
dr. petrylak on imaging approaches in prostate cancer
-
59:16
covid-19 and the immune response with dr. donna farber
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
0:34
dr. petrylak discusses custirsen as a potential treatment for prostate cancer
-
16:26
covid-19 pandemic update 101: t cell immunity vs. antibodies & prior exposure to other coronaviruses
-
0:25
daniel p. petrylak, md, on the role of dna repair gene mutations in metastatic urothelial carcinoma
-
40:54
the immunology of covid-19: pathology and clinical implications - presented by dr alex richter
-
0:58
daniel p. petrylak, md, on immunotherapy & chemotherapy combinations in metastatic bladder cancer
-
0:39
daniel petrylak, md, on the current role of ctc tumor cell components via liquid biopsy pc treatment
-
1:01
dr. petrylak on novel imaging modalities in prostate cancer